Review



cd73 blocking antibody n 4  (Bio X Cell)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Bio X Cell cd73 blocking antibody n 4
    <t>CD73/adenosine</t> pathway was upregulated in EGFR-mutant tumors. (A-D) NT5E (CD73), CD38, ADORA1 and ADORA2A RNA expression levels were compared between EGFR-mutant and WT tumors in PROSPECT, ICON and TCGA. Fold-change was calculated comparing expression of EGFR-mutant tumors to WT, using the lower expressed as the denominator. A positive fold-change value indicates overexpression in EGFR-mutant tumors and a negative value indicates decreased expression in EGFR-mutant tumors. The univariant analysis was used for p-value. (E) Feature plots showing EPCAM+ cells from the 3 single-cell RNAseq samples (right panel: cells by sample; middle panel: cells by malignant versus normal; left panel, the expression levels of NT5E in each cell) (F). Porportion of NT5E expression cells in each sample. (G) phosphorylated EGFR, CD73 and CD38 protein levels were compared between EGFR-mutant and WT tumors in the ICON cohort, from the reverse-phase protein array (RPPA).
    Cd73 Blocking Antibody N 4, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 93/100, based on 47 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd73 blocking antibody n 4/product/Bio X Cell
    Average 93 stars, based on 47 article reviews
    cd73 blocking antibody n 4 - by Bioz Stars, 2026-03
    93/100 stars

    Images

    1) Product Images from "Characterization of the immune landscape of EGFR -mutant NSCLC identifies CD73/adenosine pathway as a potential therapeutic target"

    Article Title: Characterization of the immune landscape of EGFR -mutant NSCLC identifies CD73/adenosine pathway as a potential therapeutic target

    Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

    doi: 10.1016/j.jtho.2020.12.010

    CD73/adenosine pathway was upregulated in EGFR-mutant tumors. (A-D) NT5E (CD73), CD38, ADORA1 and ADORA2A RNA expression levels were compared between EGFR-mutant and WT tumors in PROSPECT, ICON and TCGA. Fold-change was calculated comparing expression of EGFR-mutant tumors to WT, using the lower expressed as the denominator. A positive fold-change value indicates overexpression in EGFR-mutant tumors and a negative value indicates decreased expression in EGFR-mutant tumors. The univariant analysis was used for p-value. (E) Feature plots showing EPCAM+ cells from the 3 single-cell RNAseq samples (right panel: cells by sample; middle panel: cells by malignant versus normal; left panel, the expression levels of NT5E in each cell) (F). Porportion of NT5E expression cells in each sample. (G) phosphorylated EGFR, CD73 and CD38 protein levels were compared between EGFR-mutant and WT tumors in the ICON cohort, from the reverse-phase protein array (RPPA).
    Figure Legend Snippet: CD73/adenosine pathway was upregulated in EGFR-mutant tumors. (A-D) NT5E (CD73), CD38, ADORA1 and ADORA2A RNA expression levels were compared between EGFR-mutant and WT tumors in PROSPECT, ICON and TCGA. Fold-change was calculated comparing expression of EGFR-mutant tumors to WT, using the lower expressed as the denominator. A positive fold-change value indicates overexpression in EGFR-mutant tumors and a negative value indicates decreased expression in EGFR-mutant tumors. The univariant analysis was used for p-value. (E) Feature plots showing EPCAM+ cells from the 3 single-cell RNAseq samples (right panel: cells by sample; middle panel: cells by malignant versus normal; left panel, the expression levels of NT5E in each cell) (F). Porportion of NT5E expression cells in each sample. (G) phosphorylated EGFR, CD73 and CD38 protein levels were compared between EGFR-mutant and WT tumors in the ICON cohort, from the reverse-phase protein array (RPPA).

    Techniques Used: Mutagenesis, RNA Expression, Expressing, Over Expression, Protein Array

    CD73 blockade modulates T cell composition and function in EGFR-mutant non-small cell lung cancer cells. (A) CD73 cell surface expression on H1975 cells was assessed by flow cytometry with or without control and CD73 siRNAs. (B) Healthy donor PBMCs were incubated with conditioned median collected from H1975 cells after siRNA treatment. T regulatory cell population was assessed in each condition by flow cytometry using CD4+ and FoxP3+ as markers. (C) Healthy donor PBMCs were incubated with conditioned median collected from H1975 cells or H1975 after recombinant CD73 overexpression. T regulatory cell population was assessed by flow cytometry using CD4+ and FoxP3+ as markers. (D) Healthy donor PBMCs were co-cultured with H1975 cells with anti-CD73 and anti-PD-1 treatment, alone or in combination. Percent of tumor cell lysis was assessed using cytotoxicity assay. (E) Healthy donor PBMCs were co-cultured with H1975 cells with anti-CD73 and anti-PD-1 treatment, alone or in combination. The cell medium was collected and assessed for interferon release by ELISA INF-gamma assay. Student t-test was used, statistical significance: * indicates p value less than 0.05, ** indicates p value less than 0.005, *** indicates p value less than 0.0005, and **** indicates p value less than 0.0001.
    Figure Legend Snippet: CD73 blockade modulates T cell composition and function in EGFR-mutant non-small cell lung cancer cells. (A) CD73 cell surface expression on H1975 cells was assessed by flow cytometry with or without control and CD73 siRNAs. (B) Healthy donor PBMCs were incubated with conditioned median collected from H1975 cells after siRNA treatment. T regulatory cell population was assessed in each condition by flow cytometry using CD4+ and FoxP3+ as markers. (C) Healthy donor PBMCs were incubated with conditioned median collected from H1975 cells or H1975 after recombinant CD73 overexpression. T regulatory cell population was assessed by flow cytometry using CD4+ and FoxP3+ as markers. (D) Healthy donor PBMCs were co-cultured with H1975 cells with anti-CD73 and anti-PD-1 treatment, alone or in combination. Percent of tumor cell lysis was assessed using cytotoxicity assay. (E) Healthy donor PBMCs were co-cultured with H1975 cells with anti-CD73 and anti-PD-1 treatment, alone or in combination. The cell medium was collected and assessed for interferon release by ELISA INF-gamma assay. Student t-test was used, statistical significance: * indicates p value less than 0.05, ** indicates p value less than 0.005, *** indicates p value less than 0.0005, and **** indicates p value less than 0.0001.

    Techniques Used: Mutagenesis, Expressing, Flow Cytometry, Incubation, Recombinant, Over Expression, Cell Culture, Lysis, Cytotoxicity Assay, Enzyme-linked Immunosorbent Assay

    Anti-CD73 therapy-induced tumor reduction in EGFR-mutant murine lung cancers. (A) NT5E (CD73) and ADORA1 RNA expression levels in EGFR-mutant tumors and normal lung. (B) adenosine and AMP metabolite levels in EGFR-mutant tumors and normal lung. (C) CD73 immunohistochemistry for EGFR-mutant tumors and adjacent normal lung. (D) The change of tumor sizes with 2 weeks of treatment was documented and compared between vehicle-treated and anti-CD73 treated groups.
    Figure Legend Snippet: Anti-CD73 therapy-induced tumor reduction in EGFR-mutant murine lung cancers. (A) NT5E (CD73) and ADORA1 RNA expression levels in EGFR-mutant tumors and normal lung. (B) adenosine and AMP metabolite levels in EGFR-mutant tumors and normal lung. (C) CD73 immunohistochemistry for EGFR-mutant tumors and adjacent normal lung. (D) The change of tumor sizes with 2 weeks of treatment was documented and compared between vehicle-treated and anti-CD73 treated groups.

    Techniques Used: Mutagenesis, RNA Expression, Immunohistochemistry



    Similar Products

    cd73 blocking antibody n 4  (Bio X Cell)
    93
    Bio X Cell cd73 blocking antibody n 4
    <t>CD73/adenosine</t> pathway was upregulated in EGFR-mutant tumors. (A-D) NT5E (CD73), CD38, ADORA1 and ADORA2A RNA expression levels were compared between EGFR-mutant and WT tumors in PROSPECT, ICON and TCGA. Fold-change was calculated comparing expression of EGFR-mutant tumors to WT, using the lower expressed as the denominator. A positive fold-change value indicates overexpression in EGFR-mutant tumors and a negative value indicates decreased expression in EGFR-mutant tumors. The univariant analysis was used for p-value. (E) Feature plots showing EPCAM+ cells from the 3 single-cell RNAseq samples (right panel: cells by sample; middle panel: cells by malignant versus normal; left panel, the expression levels of NT5E in each cell) (F). Porportion of NT5E expression cells in each sample. (G) phosphorylated EGFR, CD73 and CD38 protein levels were compared between EGFR-mutant and WT tumors in the ICON cohort, from the reverse-phase protein array (RPPA).
    Cd73 Blocking Antibody N 4, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd73 blocking antibody n 4/product/Bio X Cell
    Average 93 stars, based on 1 article reviews
    cd73 blocking antibody n 4 - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    CD73/adenosine pathway was upregulated in EGFR-mutant tumors. (A-D) NT5E (CD73), CD38, ADORA1 and ADORA2A RNA expression levels were compared between EGFR-mutant and WT tumors in PROSPECT, ICON and TCGA. Fold-change was calculated comparing expression of EGFR-mutant tumors to WT, using the lower expressed as the denominator. A positive fold-change value indicates overexpression in EGFR-mutant tumors and a negative value indicates decreased expression in EGFR-mutant tumors. The univariant analysis was used for p-value. (E) Feature plots showing EPCAM+ cells from the 3 single-cell RNAseq samples (right panel: cells by sample; middle panel: cells by malignant versus normal; left panel, the expression levels of NT5E in each cell) (F). Porportion of NT5E expression cells in each sample. (G) phosphorylated EGFR, CD73 and CD38 protein levels were compared between EGFR-mutant and WT tumors in the ICON cohort, from the reverse-phase protein array (RPPA).

    Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

    Article Title: Characterization of the immune landscape of EGFR -mutant NSCLC identifies CD73/adenosine pathway as a potential therapeutic target

    doi: 10.1016/j.jtho.2020.12.010

    Figure Lengend Snippet: CD73/adenosine pathway was upregulated in EGFR-mutant tumors. (A-D) NT5E (CD73), CD38, ADORA1 and ADORA2A RNA expression levels were compared between EGFR-mutant and WT tumors in PROSPECT, ICON and TCGA. Fold-change was calculated comparing expression of EGFR-mutant tumors to WT, using the lower expressed as the denominator. A positive fold-change value indicates overexpression in EGFR-mutant tumors and a negative value indicates decreased expression in EGFR-mutant tumors. The univariant analysis was used for p-value. (E) Feature plots showing EPCAM+ cells from the 3 single-cell RNAseq samples (right panel: cells by sample; middle panel: cells by malignant versus normal; left panel, the expression levels of NT5E in each cell) (F). Porportion of NT5E expression cells in each sample. (G) phosphorylated EGFR, CD73 and CD38 protein levels were compared between EGFR-mutant and WT tumors in the ICON cohort, from the reverse-phase protein array (RPPA).

    Article Snippet: Treatment studies: Once the tumors were confirmed by MRI mice were either treated with vehicle (n=6) or CD73 blocking antibody (n=4) (BioXcell, in vivo monoclonal anti-mouse CD73 antibody clone: TY/23) twice a week, 100ug/dose per mouse.

    Techniques: Mutagenesis, RNA Expression, Expressing, Over Expression, Protein Array

    CD73 blockade modulates T cell composition and function in EGFR-mutant non-small cell lung cancer cells. (A) CD73 cell surface expression on H1975 cells was assessed by flow cytometry with or without control and CD73 siRNAs. (B) Healthy donor PBMCs were incubated with conditioned median collected from H1975 cells after siRNA treatment. T regulatory cell population was assessed in each condition by flow cytometry using CD4+ and FoxP3+ as markers. (C) Healthy donor PBMCs were incubated with conditioned median collected from H1975 cells or H1975 after recombinant CD73 overexpression. T regulatory cell population was assessed by flow cytometry using CD4+ and FoxP3+ as markers. (D) Healthy donor PBMCs were co-cultured with H1975 cells with anti-CD73 and anti-PD-1 treatment, alone or in combination. Percent of tumor cell lysis was assessed using cytotoxicity assay. (E) Healthy donor PBMCs were co-cultured with H1975 cells with anti-CD73 and anti-PD-1 treatment, alone or in combination. The cell medium was collected and assessed for interferon release by ELISA INF-gamma assay. Student t-test was used, statistical significance: * indicates p value less than 0.05, ** indicates p value less than 0.005, *** indicates p value less than 0.0005, and **** indicates p value less than 0.0001.

    Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

    Article Title: Characterization of the immune landscape of EGFR -mutant NSCLC identifies CD73/adenosine pathway as a potential therapeutic target

    doi: 10.1016/j.jtho.2020.12.010

    Figure Lengend Snippet: CD73 blockade modulates T cell composition and function in EGFR-mutant non-small cell lung cancer cells. (A) CD73 cell surface expression on H1975 cells was assessed by flow cytometry with or without control and CD73 siRNAs. (B) Healthy donor PBMCs were incubated with conditioned median collected from H1975 cells after siRNA treatment. T regulatory cell population was assessed in each condition by flow cytometry using CD4+ and FoxP3+ as markers. (C) Healthy donor PBMCs were incubated with conditioned median collected from H1975 cells or H1975 after recombinant CD73 overexpression. T regulatory cell population was assessed by flow cytometry using CD4+ and FoxP3+ as markers. (D) Healthy donor PBMCs were co-cultured with H1975 cells with anti-CD73 and anti-PD-1 treatment, alone or in combination. Percent of tumor cell lysis was assessed using cytotoxicity assay. (E) Healthy donor PBMCs were co-cultured with H1975 cells with anti-CD73 and anti-PD-1 treatment, alone or in combination. The cell medium was collected and assessed for interferon release by ELISA INF-gamma assay. Student t-test was used, statistical significance: * indicates p value less than 0.05, ** indicates p value less than 0.005, *** indicates p value less than 0.0005, and **** indicates p value less than 0.0001.

    Article Snippet: Treatment studies: Once the tumors were confirmed by MRI mice were either treated with vehicle (n=6) or CD73 blocking antibody (n=4) (BioXcell, in vivo monoclonal anti-mouse CD73 antibody clone: TY/23) twice a week, 100ug/dose per mouse.

    Techniques: Mutagenesis, Expressing, Flow Cytometry, Incubation, Recombinant, Over Expression, Cell Culture, Lysis, Cytotoxicity Assay, Enzyme-linked Immunosorbent Assay

    Anti-CD73 therapy-induced tumor reduction in EGFR-mutant murine lung cancers. (A) NT5E (CD73) and ADORA1 RNA expression levels in EGFR-mutant tumors and normal lung. (B) adenosine and AMP metabolite levels in EGFR-mutant tumors and normal lung. (C) CD73 immunohistochemistry for EGFR-mutant tumors and adjacent normal lung. (D) The change of tumor sizes with 2 weeks of treatment was documented and compared between vehicle-treated and anti-CD73 treated groups.

    Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

    Article Title: Characterization of the immune landscape of EGFR -mutant NSCLC identifies CD73/adenosine pathway as a potential therapeutic target

    doi: 10.1016/j.jtho.2020.12.010

    Figure Lengend Snippet: Anti-CD73 therapy-induced tumor reduction in EGFR-mutant murine lung cancers. (A) NT5E (CD73) and ADORA1 RNA expression levels in EGFR-mutant tumors and normal lung. (B) adenosine and AMP metabolite levels in EGFR-mutant tumors and normal lung. (C) CD73 immunohistochemistry for EGFR-mutant tumors and adjacent normal lung. (D) The change of tumor sizes with 2 weeks of treatment was documented and compared between vehicle-treated and anti-CD73 treated groups.

    Article Snippet: Treatment studies: Once the tumors were confirmed by MRI mice were either treated with vehicle (n=6) or CD73 blocking antibody (n=4) (BioXcell, in vivo monoclonal anti-mouse CD73 antibody clone: TY/23) twice a week, 100ug/dose per mouse.

    Techniques: Mutagenesis, RNA Expression, Immunohistochemistry